Mary Coleman
Contatto Relazioni con gli Investitori presso CATALYST PHARMACEUTICALS, INC.
Profilo
Mary Coleman is currently the Head-Investor Relations Contact at Catalyst Pharmaceuticals, Inc. She previously worked as the Senior Director-Investor Relations at Savient Pharmaceuticals, Inc., Vice President-Investor Relations & Communications at BioDelivery Sciences International, Inc., Head-Investor Relations at Agile Therapeutics, Inc., and Vice President-Investor Relations at BioXcel Therapeutics, Inc. Ms. Coleman completed her undergraduate degree at Bowling Green State University.
Posizioni attive di Mary Coleman
| Società | Posizione | Inizio |
|---|---|---|
| CATALYST PHARMACEUTICALS, INC. | Contatto Relazioni con gli Investitori | 16/08/2021 |
Precedenti posizioni note di Mary Coleman
| Società | Posizione | Fine |
|---|---|---|
| BIOXCEL THERAPEUTICS, INC. | Contatto Relazioni con gli Investitori | - |
| AGILE THERAPEUTICS, INC. | Contatto Relazioni con gli Investitori | - |
| BIODELIVERY SCIENCES INTERNATIONAL, INC. | Contatto Relazioni con gli Investitori | - |
| SAVIENT PHARMACEUTICALS INC | Contatto Relazioni con gli Investitori | - |
Formazione di Mary Coleman
| Bowling Green State University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 3 |
|---|---|
| AGILE THERAPEUTICS, INC. | Health Technology |
| CATALYST PHARMACEUTICALS, INC. | Health Technology |
| BIOXCEL THERAPEUTICS, INC. | Health Technology |
| Aziende private | 2 |
|---|---|
Savient Pharmaceuticals, Inc.
 Savient Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Savient Pharmaceuticals, Inc. operates as a specialty biopharmaceutical company, which develops, manufactures and markets pharmaceutical products. The company focuses on developing and commercializing KRYSTEXXA for the treatment of chronic gout in adult patients who do not respond to conventional therapy. It also sells and distributes branded and generic versions of oxandrolone, a drug used to promote weight gain following involuntary weight loss. The company was founded in 1980 is headquartered in East Brunswick, NJ. | Health Technology |
BioDelivery Sciences International, Inc.
 BioDelivery Sciences International, Inc. Pharmaceuticals: MajorHealth Technology BioDelivery Sciences International, Inc. operates as a pharmaceutical company engaged in the development and commercialization of new applications of approved therapeutics to address important unmet medical needs. Its products include Symproic and Belbuca. The company was founded on January 6, 1997 and is headquartered in Raleigh, NC. | Health Technology |
- Borsa valori
- Insiders
- Mary Coleman
